Skip to main content
Signal8

Radnostix, Inc. Reports FY2026 3rd Quarter and Nine Months Results - Theranostics Sales Up 15% Year-over-Year, Signs Agreement to Sell Fluorine Products/DUF6 Assets to Nano Nuclear Energy, Submits Type II DMF for Sodium Iodide I-131 API

$INISPress releaseNov 16, 2026, 12:05 PM ETRead the release

Radnostix reported Q3 2026 revenue of $2.57 million, down 22% year-over-year, with the nine-month top line down 25% to $7.62 million and net loss widening to $0.84 million for the quarter. The declines were driven by delayed Cobalt contracts awaiting NRC sealed-source amendments, a global cobalt-57 supply interruption, and two voluntary Theranostics recalls — though Theranostics sales grew 15% YoY and Gd-153 shipments resumed after a multi-year outage.

Key figures

Revenue
2571035
Guidance
Delayed ~$1.2 million of contracted Cobalt sales moved from 2H 2026 to Q1 2027; EasyFill and RadVent commercialization targeted Q1 2027
Revenue Yoy
-22%
Deal Value Usd
13500000
Credit facility
$1.0 million revolving line of credit with Bank of Commerce, 12-month term, prime rate, secured
Q3 gross margin
59%
Restricted cash
1530000
Nine month revenue
7621744
Theranostics q3 yoy
15%
Cobalt q3 revenue yoy
-88%
Nine month revenue yoy
-25%
Nine month gross margin
53%
Theranostics q3 revenue
1710000
Recall lost revenue estimate
850000

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.